CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 89 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-02 | Cherington Charles Director | Purchase · Warrants (right to buy) | +523,512 | $0.13 | $65K | 523,512 |
| 2022-12-02 | Singer Nicholas Jason Director | Purchase | +70,822 | $3.28 | $232K | 121,822 |
| 2022-12-02 | Singer Nicholas Jason Director | Purchase | +212,464 | $3.28 | $697K | 266,214 |
| 2022-12-02 | Singer Nicholas Jason Director | Purchase · Warrants (right to buy) | +141,644 | $0.13 | $18K | 141,644 |
| 2022-12-02 | Singer Nicholas Jason Director | Purchase · Warrants (right to buy) | +424,928 | $0.13 | $53K | 424,928 |
| 2022-12-02 | HALPERN JOHN D 10% owner | Purchase | +335,920 | $3.28 | $1.1M | 450,961 |
| 2022-12-02 | HALPERN JOHN D 10% owner | Purchase · Warrants (Right to Purchase) | +671,840 | $0.13 | $84K | 671,840 |
| 2022-09-20 | Sidhu Roger Chief Medical Officer | Option exercise | +20,163 | 20,163 | ||
| 2022-09-20 | Sidhu Roger Chief Medical Officer | Option exercise · Restricted Stock Units | −20,163 | 60,487 | ||
| 2022-08-01 | Wexler William A. Director | Grant or award · Stock Option (right to buy) | +152,100 | 152,100 | ||
| 2022-08-01 | Wexler William A. Director | Grant or award · Stock Option (right to buy) | +165,800 | 165,800 | ||
| 2022-08-01 | Angel Matthew Interim President and CEO | Grant or award · Stock Option (right to buy) | +2,487,003 | 2,487,003 | ||
| 2022-08-01 | Cherington Charles Director | Grant or award · Stock Option (right to buy) | +215,100 | 215,100 | ||
| 2022-08-01 | Cherington Charles Director | Grant or award · Stock Option (right to buy) | +165,800 | 165,800 | ||
| 2022-08-01 | Fiore Gregory Director | Grant or award · Stock Option (right to buy) | +95,100 | 95,100 | ||
| 2022-08-01 | Fiore Gregory Director | Grant or award · Stock Option (right to buy) | +165,800 | 165,800 | ||
| 2022-08-01 | Singer Nicholas Jason Director | Grant or award · Stock Option (right to buy) | +146,100 | 146,100 | ||
| 2022-08-01 | Singer Nicholas Jason Director | Grant or award · Stock Option (right to buy) | +165,800 | 165,800 | ||
| 2022-06-28 | DAmour Kevin Chief Scientific Officer | Option exercise | +17,573 | 17,573 | ||
| 2022-06-28 | DAmour Kevin Chief Scientific Officer | Shares withheld for taxes | −6,077 | $0.55 | $3K | 11,496 |
Page 5 of 33 · 657 trades